CLINICAL TRIALS PROFILE FOR PERFOROMIST
✉ Email this page to a colleague
All Clinical Trials for PERFOROMIST
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00633776 ↗ | Perforomist Versus Foradil Evaluated by Inspiratory Capacity and High Resolution Computed Tomography (HRCT) | Withdrawn | Dey, L.P. | Phase 4 | 2008-03-01 | The purpose of this study is to compare the effects of nebulized formoterol fumarate (Perforomist) to dry-powder inhaler formoterol fumarate (Foradil). Perforomist is a solution that is made into very fine spray (using a nebulizer) that is then breathed in over 10-15 minutes. Foradil is taken in a single quick, deep inhalation. |
| NCT00633776 ↗ | Perforomist Versus Foradil Evaluated by Inspiratory Capacity and High Resolution Computed Tomography (HRCT) | Withdrawn | University of California, Los Angeles | Phase 4 | 2008-03-01 | The purpose of this study is to compare the effects of nebulized formoterol fumarate (Perforomist) to dry-powder inhaler formoterol fumarate (Foradil). Perforomist is a solution that is made into very fine spray (using a nebulizer) that is then breathed in over 10-15 minutes. Foradil is taken in a single quick, deep inhalation. |
| NCT01488019 ↗ | Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate) | Completed | Dey | Phase 4 | 2012-03-01 | This study is a multi-center, randomized, placebo-controlled study to evaluate the long-term safety of Perforomist® inhalation therapy in subjects with Chronic Obstructive Pulmonary Disease (COPD). Individual participation is approximately 54 weeks, including 52 weeks of double-blind treatment. |
| NCT02291016 ↗ | COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers | Completed | Mylan Specialty L.P. | N/A | 2015-02-01 | The purpose of this study is to compare drug delivery and lung function after treatment with formoterol from a nebulizer versus a dry powder inhaler (DPI) in patients recovering from severe exacerbations of COPD. This is to determine if one device is superior in providing better lung function and drug deposition in this clinical setting. |
| NCT02291016 ↗ | COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers | Completed | University of Tennessee Graduate School of Medicine | N/A | 2015-02-01 | The purpose of this study is to compare drug delivery and lung function after treatment with formoterol from a nebulizer versus a dry powder inhaler (DPI) in patients recovering from severe exacerbations of COPD. This is to determine if one device is superior in providing better lung function and drug deposition in this clinical setting. |
| NCT02796651 ↗ | Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb) | Completed | Parexel | Phase 2 | 2016-06-30 | To assess the bronchodilation of three doses of formoterol fumarate (6 μg, 12 μg and 24 μg) twice daily (BID) administered via Pressair® compared to placebo and to open-label nebulized formoterol fumarate (20 μg and 40 μg). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PERFOROMIST
Condition Name
Clinical Trial Locations for PERFOROMIST
Trials by Country
Clinical Trial Progress for PERFOROMIST
Clinical Trial Phase
Clinical Trial Sponsors for PERFOROMIST
Sponsor Name
